Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous barsoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl.